The purpose of this study is to assess the effectiveness and safety of a once weekly dose of Exenatide injection on type 2 diabetes, as well as its effect on cardiovascular disease.
Exenatide or placebo will be given once weekly. Exenatide is currently approved by the U.S. Food and Drug Administration when given twice per day.
This study is intended for patients who are having difficulty controlling their blood sugars and already have cardiovascular disease.
You may qualify if you meet the following requirements:
The study is expected to last at least four years.
Qualified participants will be compensated for the visits completed.
For more information, contact Mary Furst at 919-681-3574 or email@example.com.